Group items tagged

FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE). Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these products to ensure that "pharmacies are not faced with dispensing these sensors at a loss." Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items. Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff. As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any discount deduction.

Weed Oil For Sale Have you been in search of cannabis oil for sale ? In need of thc oil for sale ? Medical Marijuana Buds is your answer. Cannabis oil is one of the most unusual oil amongst the oil range, simply because of the plant from which it is gotten from. Although cannabis and hemp have been used over the years as a natural growing herb, its awareness as a drug in certain parts of the world have strained the relationship between it's users on one hand and legal authorities on the other hand . Not withstanding, Cannabis essential oil is a very useful oil, and is widely regarded as one of the most effective oils for dealing with certain illnesses. Cannabis essential oil is gotten steam distilling the flowers and upper leaves of cannabis plants using steam. THC Oil For Sale Online and enjoy these Benefits: - Anxiety and Stress - Appetite Booster - Pain Reliever - Cancer Prevention - Heart Health - Skin Protection - Glaucoma - Headaches and Migraines Despite the fact that this list clearly shows that cannabis essential oil can effectively be used to cure most of our common health conditions, it still doesn't cancel the fact that it is a potent chemical substance extracted from a plant with psychotropic substances. As such, great care should be taken on its use with respect to the quantity and conditions under which it is being used. It is adviceable to always consult a professional about mixing essential oils and present medications before adding any new elements into your health regime. Medical cannabis oil for sale We do have medical cannabis oil for sale at our online shop which is cheap and affordable for all our customers. Our Cannabis are of great Quality and our standards are incomparable. Purchase from us and get the best for less. Note: If you are looking to buy Cannabis Oil online, hash oil for sale, Medical Marijuana Buds is the right place for you. Feel free to contact our customer service or live help assistance for wha

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE's technology appraisal process for CKD. Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system. "Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse," Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

Growing financial pressures has dented pharmacists' confidence, despite an anticipated increase in profits in the current year, latest Lloyds Bank Healthcare Confidence Index revealed on Tuesday (November 9). Though short-term confidence among pharmacists increased for the fifth consecutive year, ticking up from 27 to 29, the sector's long-term belief fell from -34 to -42. Martyn Kendrick, UK head of healthcare banking services at Lloyds Bank, said: "While pharmacists' confidence has declined somewhat, their short-term outlook has improved for another year, painting a picture of a sector that has begun to bounce back." He added that "pharmacists have performed an invaluable service during the lockdown, confirming their place at the heart of our communities." The index, a survey of pharmacists, GPs and dentists, has run annually since 2011 and gives a detailed overview of the sector.

There is still a long way to go to achieve gender equality in pharmacy in both academia and profession, Royal Pharmaceutical Society president Claire Anderson said while addressing a webinar on 'Driving equality for women in pharmacy' today (November 19). Sharing her personal experience, Anderson, who earlier worked as an academic, said: "I was the first ever female professor in the School of Pharmacy at Nottingham when I was appointed as professor in 2003, and at that point, only 11 per cent of professors in my university were female." She acknowledged that the situation has changed since then, but "there's still a very long way to go to achieve gender equity in most of academia, and in pharmacy, in particular." She added that the profession has ensured safe spaces for women but noted that is not enough, as gender equity is vital to achieve healthier and safer societies. "And although our work on equality, diversity and inclusion is progressing very well, I think we're still not there. It's a journey and there's much to be achieved."

E-pharmacy, a digital platform also known as internet pharmacy or online pharmacy, has emerged as an escape route to longstanding queues at pharmacy stores across almost all regions of the world, especially during the Covid-19 health crisis realm. They have long been recognised to act promptly in public health response, like ensuring an effective medicine supply system, resolving and monitoring drug shortage issues, educating about the proper use of PPE, promoting remote pharmacy services, and conducting drug evaluation and active surveillance. These factors will support in easing the load on healthcare facilities during the ongoing pandemic, eventually adding value to patients and the healthcare system. Overall, the e-pharmacy market size is expanding in terms of valuation on the back of regulations and standards laid by the respective governments. As per a recent study by Global Market Insights, the global e-pharmacy industry accounted for a business share of $68 billion in 2021 with an anticipated growth rate of 16.8 per cent through 2028.

The European Parliament on Thursday adopted a proposal from Brussels to ensure the continued supply of medicines from Britain to Northern Ireland - an issue that had dogged the bloc since London left it. "Great news from the @Europarl_EN today with the overwhelmingly positive vote to ensure the continued supply of medicines to Northern Ireland," tweeted Maros Sefcovic, European Commission vice president who had been leading discussions with London. "The EU is delivering on this lasting solution for Northern Ireland in record time," he added, though the EU Council must give final approval. Britain itself has yet to give formal approval on a move that would avoid potential disruption of supplies as London wants an overall accord for matters pertaining to the Northern Ireland protocol governing post-Brexit trade.

The Pharmacists' Defence Association (PDA) has raised concerns over "a prominent pharmacist's call to create a sector 'blacklist' for locums regarding disputes over rates." A few contractors took it to the Twitter to share screenshots of the messages by locums demanding more pay, which led to the call for 'blacklisting' those locums. "The motivation regarding the current talk of creating a blacklist seems intrinsically tied to hourly rates. Although there are occasional and isolated anecdotal reports on social media of alleged incidents of locums seeking higher rates than already agreed, these are far outstripped by reports of pharmacy businesses unwilling to negotiate and who do not want to pay the necessary rate to engage a locum and instead have set capped or fixed rates," said the PDA. It added that all parties should honour agreements they enter into, including a pharmacy's commitment to the NHS that it will open at set times to provide pharmaceutical services to patients and the public.

Aspen has committed not to charge more for its six generic cancer drugs for the next 10 years in the UK, according to the Competition and Markets Authority (CMA). The CMA also clarified that "although these commitments were offered while the UK was a part of the European Union" they remain "legally binding". It added: "The CMA has now assisted the NHS to secure binding undertakings from Aspen, under the law of England and Wales, which enshrine the UK elements of the commitments and are enforceable by UK courts, including in relation to the supply of these drugs in Northern Ireland and Scotland." This allows NHS to monitor and ensure compliance by Aspen following the UK's exit from the EU. In 2017, the European Commission began an investigation into Aspen over concerns that the company had engaged in excessive pricing for 6 off-patent cancer medicines.

Sixty-seven per cent of UK independent pharmacists say the pandemic has positively changed how patients view the clinical services offered by community pharmacy. The research - carried out with an independent panel of more than 100 community pharmacists - revealed that 35 per cent of them had increased their clinical services to fulfil patient demand during the pandemic. Seventeen per cent said they had expanded their private clinical services such as vaccinations and dermatology, with a further 17 per cent adding sexual health services such as emergency contraception and chlamydia screening in their services offer. Thirty per cent introduced NHS health checks and emergency supply NHS services during the pandemic.

England won't have any new Covid-19 restrictions before the end of 2021, health secretary Sajid Javid said on Monday (December 27) whilst the government awaits more evidence on whether the NHS can cope with high infection rates in the new year. "There will be no further measures before the new year," Javid told reporters, adding: "When we get into the new year, of course we will see then whether we do need to take any further measures." He said that the highly transmissible Omicron variant of the virus now accounted for around 90 per cent of cases across England and urged people to celebrate New Year cautiously. The government's attention is focused on the number of patients being hospitalised with Omicron after early data last week suggested the variant carried a lower risk of admission. The latest data showed the number of patients in hospital in England with Covid-19 was its highest since March, at 8,474, but a long way off peaks above 34,000 in January. A combination of factors, including Britain's vaccination programme, the lag between infections and hospitalisations and the potentially less harmful effects of the Omicron variant have all been put forward by health experts as possible explanations for lower numbers.

Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England. Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab. "I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire. Those who have not been vaccinated are "eight times more likely to get into hospital," he warned. The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.

Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list. Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others. "That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it. Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK. His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.

The 21st edition of the Pharmacy Business Awards have been postponed due to a dramatic rise in the number of Omicron cases nationwide in recent months. The in-person event - initially scheduled to be held on February 3 - will now be held on Wednesday March 23 in central London. The awards dinner hosted by the Asian Media Group - owners of Pharmacy Business - was initially scheduled to be held on February 3. "Given the uncertainties around Omicron and the impact it could have on our community, we have taken the difficult decision to postpone the twenty-first edition of the Pharmacy Business Awards," an AMG spokesperson said, adding: "We feel this is the best and safest decision for our award winners, guests and partners."

Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27). In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work. From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily. Besides, the legal mandate to wear face masks will go away from next week. Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign". He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose. "Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over". "I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."

Pharmacists' Defence Association (PDA) members working for Boots have raised concerns over possible reduction in their pay following the multiple's proposed changes to some pharmacies' opening hours. Member pharmacists have expressed concerns as "despite verbal assurances that the company aim to minimise pharmacist job losses, they are being told that proposed changes will reduce their income if they remain with the company," PDA has stated. PDA added that several pharmacists have been told that the proposed reduction to their hours will be more than 10 per cent, which could result in reduction in pay every month. Salary cuts could render future employment unsuitable and might force pharmacists to leave the company with redundancy, the association said.

Provision of free lateral flow tests could end in the UK, and prime minister Boris Johnson is expected to make the big announcement within weeks, The Sunday Times has reported. The report said that in future free test kits could be provided only in high-risk settings such as care homes, hospitals and schools, and to people with symptoms, and contact tracing by NHS Test and Trace is also expected to be scaled back. The newspaper quoted a senior Whitehall source as saying: "I don't think we are in a world where we can continue to hand out free lateral flow tests to everybody. "It's likely we will move to a scenario where there is less testing, but we have a capacity to ramp it up if necessary." It added that more than £6 billion of public money has already been spent on mass testing. Separately, Dr Clive Dix, former chairman of the country's vaccine task force said that Covid-19 should now be treated as a flu, and mass vaccination campaigns should end after the booster shots in the UK.

Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations. Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain. The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care. It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients. In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.

Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused. GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news. Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. "As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.

It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant. "It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months. "That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.